Life Cycle Management

What We Are Working On

In addition to our approved product, Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s pipeline includes studies being done in gynecological, gastrointestinal, genitourinary and other types of solid tumors to enable medical adoption of Lymphoseek to the broader imaging market. We will develop in collaboration with the medical community and potentially other corporate partners, ways to apply lymphatic mapping where it has the potential to become the standard-of-care.  These activities represent important steps forward in bringing new and better outcomes to people with cancer.

Approved Indications

Market Development